Sandrine Marreaud

Sandrine Marreaud

UNVERIFIED PROFILE

Are you Sandrine Marreaud?   Register this Author

Register author
Sandrine Marreaud

Sandrine Marreaud

Publications by authors named "Sandrine Marreaud"

Are you Sandrine Marreaud?   Register this Author

50Publications

1405Reads

21Profile Views

A multinational, multi-tumour basket study in very rare cancer types: The European Organization for Research and Treatment of Cancer phase II 90101 'CREATE' trial.

Eur J Cancer 2019 Mar 14;109:192-195. Epub 2019 Jan 14.

Department of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium; Laboratory of Experimental Oncology, Department of Oncology, KU Leuven, Leuven, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.12.013DOI Listing
March 2019

High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008.

J Clin Oncol 2018 Sep 6:JCO2018782516. Epub 2018 Sep 6.

Jeremy Whelan, University College Hospital; Ian Judson, Institute of Cancer Research, London; Bernadette Brennan, Royal Manchester Children's Hospital, Manchester; Bruce Morland, Birmingham Children's Hospital; Keith Wheatley, University of Birmingham, Birmingham; Ian Lewis, Leeds Community Healthcare National Health Service Trust, Leeds; Alan Craft, Newcastle University, Newcastle upon Tyne, United Kingdom; Marie-Cecile Le Deley and Cyril Lervat, Centre Oscar Lambret, Lille; Gwénaël Le Teuff, Nathalie Gaspar, and Odile Oberlin, Institut Gustave Roussy, Villejuif; Jean-Yves Blay, Centre Léon Bérard; Perrine Marec-Berard, Institute of Pediatric Onco-Haematology, Lyon; Marie-Pierre Castex, Centre Hospitalier Universitaire de Toulouse, Toulouse; Jean-Claude Gentet, Centre Hospitalier Universitaire La Timone, Marseille; Marta Jimenez, Unicancer; Valerie Laurence and Jean Michon, Institut Curie, Paris; France; Uta Dirksen, Sebastian Bauer, Andreas Ranft, University Hospital Essen, Essen; Susanne Amler, Institut für Biometrie und Klinische Forschung; Wolfgang Hartmann and Heribert Juergens, Universitätsklinikum, Münster, Münster; Stefan Bielack, Klinikum Stuttgart, Stuttgart; Stefan Burdach, Comprehensive Cancer Center, München; Dagmar Dilloo, University-Clinic Bonn, Bonn; Angelika Eggert, Charité University; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Wolf-Achim Hassenpflug, University Medical Center Hamburg-Eppendorf, Hamburg; Thomas Klingebiel, Childrens University Hospital, Frankfurt; Udo Kontny, University Medical Center Aachen, Aachen; Michael Paulussen, Children's and Adolescents' Hospital, Datteln; Germany; Douglas S. Hawkins, Seattle Children's Hospital, Seattle, WA; Hans Gelderblom, Leiden University Medical Center, Leiden; Hendrik van den Berg, University of Amsterdam, Amsterdam, the Netherlands; Lars Hjorth, Skane University Hospital, Lund, Sweden; Jarmila Kruseova, Faculty Hospital Motol Prague, Prague, Czech Republic; Ruth Ladenstein, St Anna Children's Hospital and Children's Cancer Research Institute, Vienna, Austria; Sandrine Marreaud, European Organisation for Research and Treatment of Cancer, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2018.78.2516
Publisher Site
http://dx.doi.org/10.1200/JCO.2018.78.2516DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209090PMC
September 2018

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.

N Engl J Med 2018 May 15;378(19):1789-1801. Epub 2018 Apr 15.

From the Gustave Roussy Cancer Campus Grand Paris and University Paris-Saclay, Villejuif (A.M.M.E., C.R.), Hospices Civils de Lyon Cancer Institute, Cancer Research Center of Lyon, Lyon University, Lyon (S.D.), and Aix-Marseille University, Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille, Marseille (J.-J.G.) - all in France; Netherlands Cancer Institute-Antoni van Leeuwenhoek (C.U.B., A.C.J.A.) and VU University Medical Center (A.J.M.E.), Amsterdam, and Radboud University Medical Center Nijmegen, Nijmegen (R.K.) - all in the Netherlands; Azienda Ospedaliera Papa Giovanni XXIII, Bergamo (M. Mandala), Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico Fondazione G. Pascale, Naples (P.A.A.), and Universita Degli Studi Di Siena-Policlinico le Scotte, Siena (M. Maio) - all in Italy; Melanoma Institute Australia, the University of Sydney, and Mater and Royal North Shore Hospitals (G.V.L.) and Westmead and Blacktown Hospitals, Melanoma Institute Australia and the University of Sydney (M.S.C.), Sydney, Princess Alexandra Hospital, University of Queensland, Brisbane (V.A.), Alfred Hospital (A.H.) and Peter MacCallum Cancer Centre (S. Sandhu), Melbourne, VIC, and Fiona Stanley Hospital-University of Western Australia-Edith Cowan University Perth, Perth (A.K.) - all in Australia; Cancer Research Center, Moscow (M.L.); Royal Marsden Hospital, London (J.L.); Hospital Clinic Universitari de Barcelona, Barcelona (S.P.); Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland (P.R.); University Hospital Essen, Essen and German Cancer Consortium, Heidelberg (D.S.), and the Skin Cancer Center, Department of Dermatology, Hannover Medical School, Hannover (R.G.) - all in Germany; Washington University School of Medicine, St. Louis (L.H.-A.); Centre Hospitalier de l'Université de Montréal (CHUM), Centre de Recherche du CHUM, Montreal (R.J.); Christie NHS Foundation Trust, Manchester, United Kingdom (P.L.); Merck, Kenilworth, NJ (N.I.); and the European Organization for the Research and Treatment of Cancer Headquarters, Brussels (S.M., S. Suciu).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1802357DOI Listing
May 2018

Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels.

J Clin Oncol 2017 May 31;35(15):1713-1720. Epub 2017 Mar 31.

Paolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.71.0228
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.71.0228DOI Listing
May 2017

Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas.

J Clin Oncol 2015 Dec 16;33(36):4276-83. Epub 2015 Nov 16.

Paolo G. Casali, Elena Fumagalli, and Alessandro Gronchi, Fondazione Istituto di Recovero e Cura a Carattere Scientifico Istituto Nazionale Tumori, Milano; Angelo P. Dei Tos, Azienda Unità Locale Socio Sanitaria 9 Treviso, Treviso, Italy; Axel Le Cesne, Gustave Roussy, Villejuif; Antoine Italiano, Institut Bergonie, Bordeaux; Antoine Adenis, Centre Oscar Lambret, Lille; Florence Duffaud, Hôpital de La Timone, Aix-Marseille Université, Marseille; Jean-Yves Blay, Centre Leon Berard, Lyon, France; Andres Poveda Velasco, Instituto Valenciano de Oncologia, Valencia; Javier M. Broto, Hospital Universitari Son Espases, Palma de Mallorca, Spain; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park, and University of Adelaide, Adelaide, South Australia; David Goldstein, Prince of Wales Hospital, New South Wales, Sydney; John R. Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia; Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland; Peter Hohenberger, Mannheim University Medical Center, Mannheim; Jörg T. Hartmann, Christian-Albrechts University, Kiel, Germany; Ian R. Judson, Royal Marsden Hospital; Winette T.A. van der Graaf, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, United Kingdom; Hans Gelderblom, Leiden University Medical Center, Leiden; Winette T.A. van der Graaf, Radboud University Medical Center, Nijmegen, the Netherlands; Saskia Litière, and Sandrine Marréaud, European Organisation for Research and Treatment of Cancer, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/11/16/JCO.2015.62
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2015.62.4304
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.62.4304DOI Listing
December 2015

A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study).

Breast 2014 Oct 24;23(5):663-9. Epub 2014 Jul 24.

Institut Jules Bordet, Boulevard de Waterloo 121, 1000 Brussels, Belgium; Institut Jules Bordet (currently at Champalimaud Cancer Center), Av. de Brasília, s/n, 1400-038 Lisbon, Portugal. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2014.07.003DOI Listing
October 2014

Angiosarcoma: state of the art and perspectives.

Crit Rev Oncol Hematol 2011 Nov 4;80(2):257-63. Epub 2010 Nov 4.

EORTC Headquarters, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2010.10.007DOI Listing
November 2011

EORTC-GU group expert opinion on metastatic renal cell cancer.

Eur J Cancer 2009 Mar 20;45(5):765-73. Epub 2009 Jan 20.

Department of Urology, Academic Medical Center, University of Amsterdam, The Hague, BM, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2008.12.010DOI Listing
March 2009